Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Pembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Malignant Pleural Mesothelioma：Multi-Institutional, Single-Arm Phase 2 Trial

NCT06318286 is registered in ClinicalTrials.gov with Hyogo Medical University as lead sponsor.

NCT NCT06318286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06318286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Pembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Malignant Pleural Mesothelioma：Multi-Institutional, Single-Arm Phase 2 Trial
Lead sponsor
Hyogo Medical University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 13, 2024
Completion date
October 30, 2026
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesothelioma